SAN DIEGO--(BUSINESS WIRE)--Ignyta, Inc. (OTCQB:RXDX), an oncology precision medicine biotechnology company, announced today that on February 11, 2014, the Securities and Exchange Commission declared effective the company’s registration statement on Form S-1 relating to resale of up to 9,010,238 shares of Ignyta’s common stock, par value $0.00001 per share, by certain selling stockholders. The company registered these shares to satisfy commitments it made in connection with the raising of approximately $54 million in equity financing to certain institutional investors and high net worth individuals.
Help employers find you! Check out all the jobs and post your resume.
